^
Association details:
| Biomarker: | SMARCA4 mutation |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug Class: | Immunotherapy |
| Direction: | Resistant |
Evidence:
Source:
Title:
KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden
Published date:
08/28/2020
Excerpt:
...KEAP1 mutational co-occurrences, we identified four genes potentially associated with reduced efficacy of immunotherapy (KEAP1, PBRM1, SMARCA4 and STK11). Independent of the nature of co-occurring alterations, tumors with coexisting mutations (CoMut) had inferior survival as compared to single-mutant (SM) and wild-type (WT) tumors (bNGS cohort: CoMut vs SM log-rank P=0.048, CoMut vs WT log-rank P<0.001; tNGS cohort: CoMut vs SM log-rank P=0.037, CoMut vs WT log-rank P=0.006)....study indicates that coexisting alterations in a limited set of genes characterize a subset of LUAD unresponsive to immunotherapy and with high TMB.
DOI:
https://doi.org/10.1016/j.annonc.2020.08.2105
